US4900723A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination
Assignee: ER Squibb and Sons LLC
•
Filing: 1988-04-29
•
Granted: 1990-02-13
•
Expires: 2008-04-29
Abstract
Abstract A method is provided for preventing or reducing deep vein thrombosis and/or pulmonary embolism by administering a thromboxane A 2 receptor antagonist in conjunction with heparin. A combination of thromboxane A 2 receptor antagonist and heparin is also provided.
Inventors
- 👤 William A. Schumacher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:44
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
72 words
A method for preventing or reducing deep vein thrombosis, pulmonary embolism or both in a mammalian species, which comprises administering to a mammalian species in need of such treatment an effective amount of a thromboxane A 2 receptor antagonist and an effective amount of heparin, wherein the thromboxane A 2 receptor antagonist is employed in a weight ratio to the heparin of within the range of from about 0.1:1 to about 50:1.
Claim 2
Independent Claim
72 words
A method for preventing or reducing deep vein thrombosis, pulmonary embolism or both in a mammalian species, which comprises administering to a mammalian species in need of such treatment an effective amount of a thromboxane A 2 receptor antagonist and an effective amount of heparin, wherein the thromboxane A 2 receptor antagonist is employed in a weight ratio to the heparin of within the range of from about 0.1:1 to about 50:1.
Claim 3
Dependent Claim
17 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered systemically.
Claim 4
Dependent Claim
25 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered intravenously, orally, intraarterially, intrapulmonary arterially, transdermally, or by inhalation.
Claim 5
Dependent Claim
27 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered before, during or within several minutes after the administration of heparin.
Claim 6
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered during administration of heparin.
Claim 7
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane or a 7-oxabicycloheptene.
Claim 8
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane substituted amino-prostaglandin analog.
Claim 9
Dependent Claim
21 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane substituted diamide prostaglandin analog.
Claim 10
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a phenoxyalkyl carboxylic acid.
Claim 11
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a sulfonamidophenyl carboxylic acid.
Claim 12
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is an arylthioalkylphenyl carboxylic acid.
Claim 13
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is [1S-[1α,2β(5Z), 3β(1E,3R,4S),4α ]]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 14
Dependent Claim
21 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is [1S-[1β,2α(5Z),3α,4β]]-7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-ox acid or the corresponding tetrazole.
Claim 15
Dependent Claim
18 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is [1S-[1<α,2<β(Z) ,3<β,4<α]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)-amino]ace acid.
Claim 16
Dependent Claim
18 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is [1S-[1α,2β(5Z),3β,4α]]-7-[3-[[2-(phenylamino)carbonyl]-hydrazino]methyl]-7-[3 hydrazino]methyl-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 17
Dependent Claim
18 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is 4-(3-((4-chlorophenyl)-sulfonyl)propyl acetic acid.
Claim 18
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is 4-[2-(benzenesulfamido)-ethyl]phenoxy acid or 4-[2-(4-chlorobenzenesulfonamido)-ehtyl]phenylacetic acid.
Claim 19
Dependent Claim
42 words
A pharmaceutical combination for preventing or reducing deep vein thrombosis, pulmonary embolism or both, comprising a thromboxane A 2 receptor antagonist and heparin, employed in a weight ratio to each other of within the range of from about 0.1:I to about 50:1.
Claim 20
Dependent Claim
42 words
A pharmaceutical combination for preventing or reducing deep vein thrombosis, pulmonary embolism or both, comprising a thromboxane A 2 receptor antagonist and heparin, employed in a weight ratio to each other of within the range of from about 0.1:I to about 50:1.
Claim 21
Dependent Claim
33 words
The combination as defined in claim 18 wherein the thromboxane A 2 receptor antagonist is present in a weight ratio to heparin of within the range of from about 0.5:1 to about 4:1.
Claim 22
Dependent Claim
21 words
The combination as defined i claim 19 wherein the thromboxane A 2 receptor antagonist is [IS-[1β,2α(5Z),3α,4β]]-7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or the corresponding tetrazole.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-12 | 1993-08-14 | 1994-02-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-12 | 1997-08-14 | 1998-02-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-12 | 2001-08-14 | 2002-02-13 | $7700.00 | Window Closed / Lapsed |